Related Experiment Video
Updated: Dec 26, 2025
12:04
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Published on: August 14, 2012
29.4K
Evolution of Neuroendocrine Tumor Therapy
Thomas M O'Dorisio1, Alan G Harris2, M Sue O'Dorisio3
1Division of Endocrinology, University of Iowa Hospitals and Clinics, Room E401-5 GH, 200 Hawkins Drive, Iowa City, Iowa 52242, USA.
Surgical Oncology Clinics of North America
|March 11, 2020
Summary
This review covers the history of gastrointestinal endocrinology, focusing on somatostatin analogues for neuroendocrine tumors (NETs). It highlights Lu-177-DOTATATE as standard care and discusses new therapies for high-grade NETs.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Neuroendocrine tumors (NETs) involve complex peptide regulation.
- Native somatostatin and its analogues are crucial in managing NETs.
- Gastrointestinal endocrinology has evolved significantly.
Purpose of the Study:
- To review the historical development of gastroenteropancreatic neuroendocrine tumor (GEP-NET) treatments.
- To emphasize the role of somatostatin analogues in NET management.
- To discuss current and future diagnostic and therapeutic strategies for NETs.
Main Methods:
- Historical review of gastrointestinal endocrinology.
- Analysis of basic science and clinical research advancements.
- Discussion of approved and investigational therapies.
Main Results:
- Lu-177-DOTATATE is now standard care for low-grade GEP-NETs.
- Collaboration between academia and industry accelerated therapeutic development.
- New radioisotopes and compounds are under investigation for high-grade NETs.
Conclusions:
- Understanding NETs has progressed through distinct historical phases.
- Targeted therapies like Lu-177-DOTATATE have transformed GEP-NET treatment.
- Ongoing research promises improved diagnostic and therapeutic options for all NET grades.
Related Concept Videos
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
471
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
471
02:07Tumor Progression
7.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K